In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncor

This article was originally published in The Gray Sheet

Executive Summary

Submits premarket approval application Oct. 3 for the in vitro diagnostic use of its chronic myelogenous leukemia (CML) Mbcr/abl genetic test system. The company says that in multi-center trials involving close to 350 patients, the Oncor test, when used alone, "was 96.1% sensitive and 99.3% specific in detecting CML, compared to the detection rates of a combination of the best presently available methods." The Gaithersburg, Maryland-based firm estimates that its test will cost "five times less than conventional methods"
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel